Xencor, Inc.

Alex Nisthal

John R Desjarlais

Matthew J Bernett

Gregory L Moore

Michael Hedvat

Seung Yup Chu

Christine Bonzon

Rumana Rashid

Umesh Muchhal

Rajat Varma

Yoon Kyung Kim

Sung-Hyung Lee

Juan Diaz

Ke Liu

Matthew Adam Dragovich

Eric Chang

Chad Borchert

Matthew S Faber

Jing Qi

Kendra N Avery

Katrina Bykova

Nargess Hassanzadeh-Kiabi

Umesh S Muchhal

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.

Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains

Provided herein are novel antigen binding domains and antibodies (e.g., heterodimeric antibodies) that bind Prostate Specific Membrane Antigen (PSMA). In exemplary embodiments, the anti-PSMA antibodies also bind CD3. Such antibodies that bind PSMA and CD3 are useful, for example in the treatment of PSMA-related cancer.

Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3

Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

Heterodimeric antibodies that bind CD3 and CLDN6

The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).

Heterodimeric antibodies that bind fibroblast activation protein

The present invention is directed to bispecific, heterodimeric checkpoint antibodies.

Bispecific and monospecific antibodies using novel anti-PD-1 sequences

The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.

Untargeted and targeted IL-10 Fc-fusion proteins

Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.

Heterodimeric antibodies that bind CD3 and GPC3

The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Bispecific binding agents binding to CLDN18.2 and CD3

Provided herein are novel CLDN6 binding domains, and anti-CLDN6&#xd7;anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R&#x3b1; Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.

Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains

The present invention is directed to heterodimeric anti-LAG-3&#xd7;anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.

Bispecific checkpoint inhibitor antibodies

The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3).

Heterodimeric antibodies that bind ENPP3 and CD3

The present invention is directed to heterodimeric anti-PD-1 x anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.

Growing community of inventors

Monrovia, CA, United States of America

Alex Nisthal